Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab SC with rHuPH20 in Healthy Volunteers
NCT05396742Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) (5 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Absolute Bioavailability Of Ravulizumab Subcutaneous (SC)/rHuPH20 and Number of Participants Reporting Treatment-Emergent Adverse Events. Started Aug 2018; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT05396742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396742.